270 related articles for article (PubMed ID: 31598691)
21. In vitro characterization of trimegestone: a new potent and selective progestin.
Zhang Z; Lundeen SG; Zhu Y; Carver JM; Winneker RC
Steroids; 2000; 65(10-11):637-43. PubMed ID: 11108870
[TBL] [Abstract][Full Text] [Related]
22. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Chen CC; Hardy DB; Mendelson CR
J Biol Chem; 2011 Dec; 286(50):43091-102. PubMed ID: 22020934
[TBL] [Abstract][Full Text] [Related]
23. Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells.
Hegde SM; Kumar MN; Kavya K; Kumar KM; Nagesh R; Patil RH; Babu RL; Ramesh GT; Sharma SC
Mol Cell Biochem; 2016 Nov; 422(1-2):109-120. PubMed ID: 27632388
[TBL] [Abstract][Full Text] [Related]
24. Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity.
Robin-Jagerschmidt C; Wurtz JM; Guillot B; Gofflo D; Benhamou B; Vergezac A; Ossart C; Moras D; Philibert D
Mol Endocrinol; 2000 Jul; 14(7):1028-37. PubMed ID: 10894152
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of gene expression by steroid hormone receptors via a negative glucocorticoid response element: evidence for the involvement of DNA-binding and agonistic effects of the antiglucocorticoid/antiprogestin RU486.
Cairns C; Cairns W; Okret S
DNA Cell Biol; 1993 Oct; 12(8):695-702. PubMed ID: 8397827
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells.
Yin P; Roqueiro D; Huang L; Owen JK; Xie A; Navarro A; Monsivais D; Coon JS; Kim JJ; Dai Y; Bulun SE
PLoS One; 2012; 7(1):e29021. PubMed ID: 22272226
[TBL] [Abstract][Full Text] [Related]
27. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.
Daniel AR; Lange CA
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14287-92. PubMed ID: 19706513
[TBL] [Abstract][Full Text] [Related]
28. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.
Reyes D; Ballaré C; Castellano G; Soronellas D; Bagó JR; Blanco J; Beato M
Oncogene; 2014 Mar; 33(12):1570-80. PubMed ID: 23604116
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
30. Developmental and hormonal regulation of progesterone receptor A-form expression in female mouse lung in vivo: interaction with glucocorticoid receptors.
Shao R; Egecioglu E; Weijdegård B; Ljungström K; Ling C; Fernandez-Rodriguez J; Billig H
J Endocrinol; 2006 Sep; 190(3):857-70. PubMed ID: 17003286
[TBL] [Abstract][Full Text] [Related]
31. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
32. Characterization of transiently and constitutively expressed progesterone receptors: evidence for two functional states.
Smith CL; Wolford RG; O'Neill TB; Hager GL
Mol Endocrinol; 2000 Jul; 14(7):956-71. PubMed ID: 10894147
[TBL] [Abstract][Full Text] [Related]
33. Kaiso represses the expression of glucocorticoid receptor via a methylation-dependent mechanism and attenuates the anti-apoptotic activity of glucocorticoids in breast cancer cells.
Zhou L; Zhong Y; Yang FH; Li ZB; Zhou J; Liu XH; Li M; Hu F
BMB Rep; 2016 Mar; 49(3):167-72. PubMed ID: 26424557
[TBL] [Abstract][Full Text] [Related]
34. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos G; Szapary D; Smith CL; Meeker JE; Simons SS
Mol Endocrinol; 2001 Feb; 15(2):255-70. PubMed ID: 11158332
[TBL] [Abstract][Full Text] [Related]
35. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth.
Daniel AR; Qiu M; Faivre EJ; Ostrander JH; Skildum A; Lange CA
Steroids; 2007 Feb; 72(2):188-201. PubMed ID: 17173941
[TBL] [Abstract][Full Text] [Related]
36. A set of accessible enhancers enables the initial response of breast cancer cells to physiological progestin concentrations.
Zaurin R; Ferrari R; Nacht AS; Carbonell J; Le Dily F; Font-Mateu J; de Llobet Cucalon LI; Vidal E; Lioutas A; Beato M; Vicent GP
Nucleic Acids Res; 2021 Dec; 49(22):12716-12731. PubMed ID: 34850111
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
Buxant F; Engohan-Aloghe C; Noël JC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
[TBL] [Abstract][Full Text] [Related]
38. Unspecific and sequence-specific deoxyribonucleic acid binding of the partially purified human progesterone receptor.
Berkenstam A; Glaumann H; Gustafsson JA
Mol Endocrinol; 1988 Jun; 2(6):571-8. PubMed ID: 2843763
[TBL] [Abstract][Full Text] [Related]
39. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
[TBL] [Abstract][Full Text] [Related]
40. Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.
Diep CH; Knutson TP; Lange CA
Mol Cancer Res; 2016 Feb; 14(2):141-62. PubMed ID: 26577046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
